ערך בספרים למניה: Trevi Therapeutics, Inc. (TRVI)
The price trajectory of Trevi Therapeutics (TRVI) reflects the dynamics of a company minimizing internal costs by outsourcing clinical trials and formula development to third-party contractors. The business relies on the development of proprietary itch and cough remedies, which will ensure significant pricing power. The current metric stands at 2.24, while the creation of a closed therapeutic cycle around nalbuphine ER makes it difficult for patients to switch to other medications.
trevitherapeutics.com - פילוחים אנליטיים ומדדי מפתח (TRVI)
Book value per share reflects the portion of equity attributable to a single security after deducting all liabilities. This metric determines the company's actual asset base. For Trevi Therapeutics (TRVI), a niche chronic cough therapy developer, such a base is critical for funding research and development. The trend in book value per share under RAS allows for an assessment of asset resilience against risks. Steady growth in this metric confirms the issuer's long-term solvency.